Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Sophie Miriam Lanzkron, M.D., M.H.S.
Director, Sickle Cell Center for Adults, The Johns Hopkins Hospital
Associate Professor of Medicine
Expertise: Hematology, Sickle Cell Disease
Research Interests: sickle cell disease
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital
Appointment Phone: 410-955-3142
600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Dr. Sophie Lanzkron is an associate professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hematology and sickle cell disease. Dr. Lanzkron is director of the Sickle Cell Center for Adults at Johns Hopkins.
Dr. Lanzkron received her undergraduate degree in biology from Brandeis University. She earned her M.D. from Albert Einstein College of Medicine. She completed her residency at the University of Maryland Medical Center and performed her fellowship in hematology at Johns Hopkins. She joined the faculty of Johns Hopkins in 2000.
Her research focuses on sickle cell disease.
- Director, Sickle Cell Center for Adults, The Johns Hopkins Hospital
- Associate Professor of Medicine
- Associate Professor of Oncology
Centers & Institutes
- Heart and Vascular Institute
- Sickle Cell Center for Adults at Johns Hopkins
- MD, Albert Einstein College of Medicine of Yeshiva Univ (1991)
- University of Maryland Medical Center / General Internal Medicine (1994)
- Johns Hopkins University School of Medicine / Hematology (1997)
- American Board of Internal Medicine / Hematology (1996)
Research & Publications
Dr. Lanzkron's major clinical research involves the study of sickle cell disease. Her primary research interest is to understand the barriers to care for adults with sickle cell disease. In 1998, the FDA approved the use of hydroxyurea to treat patients with sickle cell disease. This approval was based on a large clinical trial centered at Johns Hopkins. The use of hydroxyurea was predicted to decrease hospitalizations and the costs of care for those with sickle cell disease. Dr. Lanzkron's research has shown that despite the approval of hydroxyurea, the costs of caring for patients with sickle cell disease have increased significantly over the last seven years. Research is ongoing to identify the factors that limit access to care for this population.
Clinical Trial Keywordssickle
Laurence B, George D, Woods D, Shosanya A, Katz RV, Lanzkron S, Diener-West M, Powe N. "The association between sickle cell disease and dental caries in African Americans." Spec Care Dentist. 2006 May-Jun;26(3):95-100.
Lanzkron S, Moliterno A, Norris EJ, Gould S, Segal J, Neurmberger E, Ness P. "Polymerized human hemoglobin use in acute chest syndrome: A case report." Transfusion. 2002 Nov;42(11):1422-7.
Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molina R, Lanzkron S, Bachier C, Nanez A, LeMaistre CF. "Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue." Bone Marrow Transplant. 2001 Jan;27(2):221-4.
Bachier CR, Gokmen E, Teale J, Lanzkron S, Childs C, Franklin W, Shpall E, Douville J, Weber S, Muller T, Armstrong D, Lemaistre CF. "Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high dose chemotherapy for breast cancer." Exp Hem. 1999 Apr;27(4):615-23.
Lanzkron SM, Collector MI , Sharkis SJ. "Homing of long-term and short-term engrafting cells in vivo." Ann N Y Acad Sci. 1999 Apr 30;872:48-54; discussion 54-6.